To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.

Inclusion Criteria:

- Healthy ,male and female subjects 18 to 55 years of age, inclusive

- Body Mass Index (BMI) of approximately 18 to 30 kg/m2, and a total body weight >50 kg
(110 lbs)

- Results of screening and clinical laboratory tests are within normal limits or
considered not clinically significant by the Principal Investigator or Sponsor

- Female subjects of childbearing potential must be using a medically acceptable form
of birth control for at least 1 month prior to screening (3 months on oral
contraceptives), e.g., oral or patch contraceptives, intrauterine device,
intramuscular injection or double-barrier and have a negative pregnancy test at
Screening and on Day 0 of each treatment period. Female subjects of nonchildbearing
potential must be amenorrheic for at least 2 years or had a hysterectomy and/or
bilateral oophorectomy.

Exclusion Criteria:

- History of hypersensitivity to acetylsalicylic acid (ASA), naproxen sodium,
acetaminophen, other non-steroidal anti-inflammatory drugs (NSAIDs), and similar
pharmacological agents or components of the products

- History of gastrointestinal bleeding or perforation, including bleeding related to
previous NSAID therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two
or more distinct episodes of proven ulceration or bleeding).

- Have taken ASA, ASA-containing products, acetaminophen or any other NSAID (OTC or
prescription) seven days prior to dosing or during the Treatment Periods, other than
study product

- Loss of blood in excess of 500 mL within 56 days of the first dose of trial treatment
(e.g., donation, plasmapheresis, or injury)

- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic
disease, or malignancies

- Positive alcohol or drug screen at Screening or on Day 0 of Treatment Periods 1,2 and
3

- Females who are pregnant or lactating